GlassScriptPhysician profile
Ulrich Starke
NPI 1114907300
$6,065.00
in general payments reported to CMS, 2019-2025
36 companies · $13.76 in 2025
The $13.76 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $947 · 2021: $1,098 · 2022: $631 · 2023: $1,328 · 2024: $1,000 · 2025: $13.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $803.68 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $627.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $563.52 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.51 | 2019-2024 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $553.31 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $504.11 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $375.53 | 2021-2024 | Ubrelvy, Synthroid, Qulipta |
| Astellas Pharma US INC | $229.15 | 2019-2024 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $212.95 | 2019-2022 | |
| Abbott Laboratories | $198.54 | 2019-2024 | Freestyle Libre, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $190.61 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $169.13 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $132.58 | 2020-2023 | Belsomra, Verquvo |
| Idorsia Pharmaceuticals US INC | $128.69 | 2022-2024 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $107.54 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $105.91 | 2019-2022 | |
| Exact Sciences Corporation | $85.02 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $59.28 | 2023 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $51.68 | 2024 | Qelbree, Xyosted |
| Dexcom, INC. | $47.08 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $45.65 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.55 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $39.44 | 2023 | Xyosted, Tlando, Nocdurna |
| Intra-Sana Laboratories | $27.16 | 2024 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Edwards Lifesciences Corporation | $26.54 | 2023 | |
| Halozyme INC | $23.88 | 2023 | |
| Itamar Medical INC | $23.67 | 2023 | Watchpatone |
| Medtronic Vascular, INC. | $20.45 | 2019 | |
| Nevro Corp. | $20.22 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.63 | 2024 | Caplyta |
| Gilead Sciences, INC. | $15.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.38 | 2019 | |
| Esperion Therapeutics, INC. | $13.50 | 2023 | Nexletol |
| Sanofi Pasteur INC. | $12.52 | 2019 | |
| Allergan, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulrich Starke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.